Published • loading... • Updated
Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial
The daily pill cut the risk of death by 60% and raised median survival to 13.2 months, RevMed said.
- Revolution Medicines announced Monday that its experimental pill reduced the risk of death by 60% in a Phase 3 Pancreatic cancer trial, with RevMed CEO Mark Goldsmith calling the results "dramatic, practice-changing outcomes."
- RAS mutations found in more than 90% of Pancreatic cancer cases drive tumor growth, which the pill targets as an alternative to cytotoxic intravenous chemotherapy, the standard treatment.
- Patients taking the pill lived 13.2 months versus 6.7 months on chemotherapy, an increase of 6.5 months, with Goldsmith noting no drug has previously shown such an overall survival benefit in a Phase 3 pancreatic trial.
- The company plans to seek Food and Drug Administration approval using a National Priority Voucher that expedites review, and Shares jumped more than 30% following Monday's announcement.
- Despite media reports identifying the company as a potential acquisition target, Revolution Medicines is conducting a Phase 3 trial for newly diagnosed patients to expand the pill's reach.
Insights by Ground AI
Podcasts & Opinions
27 Articles
27 Articles
New hopes against pancreatic cancer from an experimental pill that in phase 3, in patients with metastatic cancer, achieved a doubling of survival compared to chemo. The data...
The actions of the Revolution Medicines Inc. have been shot, registering the highest in six years, after its treatment for an aggressive form of pancreatic cancer increases the survival of patients in a final phase clinical trial, marking significant progress in the treatment of this particular fatal condition.
·Brazil
Read Full Article
Coverage Details
Total News Sources27
Leaning Left6Leaning Right2Center15Last UpdatedBias Distribution65% Center
Bias Distribution
- 65% of the sources are Center
65% Center
L 26%
C 65%
Factuality
To view factuality data please Upgrade to Premium
